166 filings
Page 7 of 9
8-K
ci3 el1paiwn
13 Feb 20
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:17pm
8-K
4h2gl07
12 Feb 20
Moderna Announces Pricing of Public Offering of Shares of Common Stock
4:55pm
424B5
s1mukbc1y4fbekbzzhpe
12 Feb 20
Prospectus supplement for primary offering
4:54pm
FWP
wagrbxbx7pdnnwn
10 Feb 20
Free writing prospectus
5:25pm
FWP
zgof7mkj
10 Feb 20
Free writing prospectus
5:23pm
424B5
0m0y7
10 Feb 20
Prospectus supplement for primary offering
5:03pm
S-3ASR
svx0k0g 5tpm01sy9wk
10 Feb 20
Automatic shelf registration
4:03pm
8-K
98vau4b pyl
3 Feb 20
Other Events
8:17am
DEFA14A
5yq2p0q tq8
3 Feb 20
Additional proxy soliciting materials
8:16am
8-K
hkg0a 7487yqr
22 Jan 20
Regulation FD Disclosure
6:06am
8-K
p542gr
6 Jan 20
Results of Operations and Financial Condition
7:00am
8-K
3ncr6eslspn
11 Dec 19
Departure of Directors or Certain Officers
5:11pm
8-K
t9vskh0o65 9i
6 Nov 19
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
7:00am
8-K
i0e4d7rqyzatag
12 Sep 19
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study
7:00am
8-K
vdhjayqg ff3aja
7 Aug 19
Moderna Provides Business Updates and Reports Second Quarter 2019
6:57am
8-K
d7va7ubgekllyqym ccd
27 Jun 19
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
2ipprkufz2mz50a 3l9
3 Jun 19
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
6:30am
DEF 14A
y4t9auc337zy7 3n9b9
15 May 19
Definitive proxy
5:15pm